Biotherapeutics News and Research

RSS

Talecris third quarter net revenue increases 2.8% to $407.0 million

Talecris Biotherapeutics Holdings Corp. today announced its financial results for the three and nine months ended September 30, 2010 and filed its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission (SEC).

29 Oct 2010

Emergent BioSolutions completes Trubion acquisition

Emergent BioSolutions Inc. today announced that it has completed the acquisition of Trubion Pharmaceuticals, Inc., following a majority vote to approve the merger by Trubion stockholders at a special meeting conducted at Trubion's Seattle headquarters on October 28, 2010. The acquisition provides Emergent with multiple, advanced stage candidates in the key disease areas of oncology and autoimmunity as well as access to novel and versatile protein therapeutic platforms.

29 Oct 2010

GTC 2010 third fiscal quarter net loss decreases to $4.5 million from $26.2 million

GTC Biotherapeutics, Inc. today reported its financial results for the third fiscal quarter ended September 30, 2010.

28 Oct 2010

Talecris announces publication of PROLASTIN-C study results for AAT deficiency in BML journal

Talecris Biotherapeutics today announced the publication of results from a study showing that PROLASTIN-C (Alpha1-Proteinase Inhibitor [Human]) (A1PI) is as effective as PROLASTIN (Alpha1-Proteinase Inhibitor [Human]) in raising levels of alpha-1 protein in patients with alpha1-antitrypsin (AAT) deficiency.

22 Oct 2010

FDA approves Gamunex-C for primary immunodeficiency treatment

Talecris Biotherapeutics announced today that the U.S. Food and Drug Administration (FDA) approved Gamunex-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) for subcutaneous administration in the treatment of primary immunodeficiency (PI).

15 Oct 2010

Synosia announces $30M Series C financing

Synosia Therapeutics, a privately held biotherapeutics company focused on neurology and psychiatry, today announced that it has raised $30M in a Series C financing round.

12 Oct 2010

Oxygen Biotherapeutics to showcase DERMACYTE oxygen-rich skin care products at Spa & Resort expo

Oxygen Biotherapeutics, Inc. will showcase for the first time its DERMACYTE oxygen-rich skin care products at the Spa & Resort/Medical Aesthetics Spa Conference and Expo at the Jacob K. Javits Convention Center in New York City starting tomorrow.

28 Sep 2010

DSMB authorizes Oxygen Biotherapeutics' next cohort of Oxycyte emulsion study in severe non-penetrating TBI

Oxygen Biotherapeutics, Inc. reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte® emulsion in patients with severe non-penetrating traumatic brain injury.

23 Sep 2010

Talecris Biotherapeutics announces 2010 eALTA award recipients

Talecris Biotherapeutics GmbH announced yesterday the recipients of the 2010 European alpha1-antitrypsin Laurell's Training Awards (eALTA). The annual awards, sponsored by Talecris, provide two fellowships of 50,000 euros to young investigators whose research aims to enhance the understanding and treatment of alpha1-antitrypsin deficiency (AAT deficiency).

21 Sep 2010

Oxygen Biotherapeutics announces CRADA Agreement amendment

Oxygen Biotherapeutics, Inc. today announced it has amended an existing Cooperative Research and Development Agreement (CRADA) with the U.S. Naval Medical Research Center (NMRC) to include preclinical trials using swine models to assess the safety and efficacy of Oxygen Biotherapeutics' proprietary Oxycyte perfluorocarbon emulsion (PFCE) for spinal cord injury (SCI) due to decompression sickness (DCS), and for hemorrhagic shock.

20 Sep 2010

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.

13 Sep 2010

Oxygen Biotherapeutics 2010 first quarter net loss increases to $3 million

Oxygen Biotherapeutics, Inc., a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced results for the fiscal year (FY) first quarter ended July 31, 2010.

10 Sep 2010

Zyngenia completes $15M Series A financing extension from NEA

Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.

8 Sep 2010

Oxygen Biotherapeutics offers traumatic brain injury trials for Israeli soldiers

Oxygen Biotherapeutics, Inc., a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced that Israeli soldiers who suffer severe traumatic brain injury (TBI) can be enrolled in the company's Phase II-b STOP-TBI trials at clinical sites in Israel.

8 Sep 2010

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene Euronext, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that they have entered into an exclusive partnership to develop and commercialize JX-594 for the treatment of solid tumors in Europe, the Commonwealth of Independent States (CIS) and the Middle East.

8 Sep 2010

Study shows DERMACYTE Oxygen Concentrate improves skin appearance

Oxygen Biotherapeutics, Inc. today announced that results from an 8-week cosmetic study showed that the topical application of DERMACYTE Oxygen Concentrate, an oxygen-rich skin care lotion, appears to improve the appearance of fine lines and the perception of skin appearance.

31 Aug 2010

Protalix common stock receives approval for Tel Aviv Stock Exchange listing

Protalix BioTherapeutics, Inc.,a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, today announced that the Company's common stock has been approved for listing on the Tel Aviv Stock Exchange in addition to its current listing on the NYSE Amex.

30 Aug 2010

Talecris and Grifols receive 'Second Request' from FTC regarding proposed merger

Talecris Biotherapeutics Holdings Corp. today announced that Talecris and Grifols S.A. have each received a request for additional information and documentary material, often referred to as a "Second Request," from the U.S. Federal Trade Commission (FTC) in connection with their proposed merger.

10 Aug 2010

Alnylam second-quarter revenues increase to $26.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2010, and company highlights.

5 Aug 2010

Caliper Life Sciences second-quarter GAAP revenue decreases 10% to $29.0 million

Caliper Life Sciences, Inc., today reported results for its second quarter ended June 30, 2010. Second quarter GAAP revenue decreased 10% to $29.0 million from $32.1 million in the same period in 2009 as a result of divestitures in 2010 and 2009. Revenue from on-going business increased 4% on a reported basis and 6% on an organic basis (which assumes constant currency).

3 Aug 2010

Biotherapeutics News and Research

Talecris third quarter net revenue increases 2.8% to $407.0 million

Emergent BioSolutions completes Trubion acquisition

GTC 2010 third fiscal quarter net loss decreases to $4.5 million from $26.2 million

Talecris announces publication of PROLASTIN-C study results for AAT deficiency in BML journal

FDA approves Gamunex-C for primary immunodeficiency treatment

Synosia announces $30M Series C financing

Oxygen Biotherapeutics to showcase DERMACYTE oxygen-rich skin care products at Spa & Resort expo

DSMB authorizes Oxygen Biotherapeutics' next cohort of Oxycyte emulsion study in severe non-penetrating TBI

Talecris Biotherapeutics announces 2010 eALTA award recipients

Oxygen Biotherapeutics announces CRADA Agreement amendment

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

Oxygen Biotherapeutics 2010 first quarter net loss increases to $3 million

Zyngenia completes $15M Series A financing extension from NEA

Oxygen Biotherapeutics offers traumatic brain injury trials for Israeli soldiers

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Study shows DERMACYTE Oxygen Concentrate improves skin appearance

Protalix common stock receives approval for Tel Aviv Stock Exchange listing

Talecris and Grifols receive 'Second Request' from FTC regarding proposed merger

Alnylam second-quarter revenues increase to $26.6 million

Caliper Life Sciences second-quarter GAAP revenue decreases 10% to $29.0 million

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring